VAP-1 inhibitor / Keio University, Mallinckrodt - LARVOL DELTA

[VIRTUAL] THE IMPACT OF GVHD ON OUTCOMES AFTER ADULT SINGLE CORD BLOOD TRANSPLANTATION IN EUROPEAN AND JAPANESE POPULATIONS: THE EUROCORD/ALWP EBMT AND JSHCT/JDCHCT COLLABORATIVE STUDY (EBMT 2021) - " The deleterious impact of severe acute GVHD was observed in both registries. On the other hand, mild GVHD, i.e. grade II acute GVHD and limited chronic GVHD showed a beneficial effect in the Japanese cohort only. This could reflect ethnic differences in UCBT outcomes and might contribute to the preference of UCBT in Japan."

Clinical • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Oncology • Transplantation • HLA-DRB1

[VIRTUAL] THE IMPACT OF GVHD ON OUTCOMES AFTER ADULT SINGLE CORD BLOOD TRANSPLANTATION IN EUROPEAN AND JAPANESE POPULATIONS: THE EUROCORD/ALWP EBMT AND JSHCT/JDCHCT COLLABORATIVE STUDY (EBMT 2021) - " The deleterious impact of severe acute GVHD was observed in both registries. On the other hand, mild GVHD, i.e. grade II acute GVHD and limited chronic GVHD showed a beneficial effect in the Japanese cohort only. This could reflect ethnic differences in UCBT outcomes and might contribute to the preference of UCBT in Japan."

Clinical • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Oncology • Transplantation • HLA-DRB1

[VIRTUAL] THE IMPACT OF GVHD ON OUTCOMES AFTER ADULT SINGLE CORD BLOOD TRANSPLANTATION IN EUROPEAN AND JAPANESE POPULATIONS: THE EUROCORD/ALWP EBMT AND JSHCT/JDCHCT COLLABORATIVE STUDY (EBMT 2021) - " The deleterious impact of severe acute GVHD was observed in both registries. On the other hand, mild GVHD, i.e. grade II acute GVHD and limited chronic GVHD showed a beneficial effect in the Japanese cohort only. This could reflect ethnic differences in UCBT outcomes and might contribute to the preference of UCBT in Japan."

Clinical • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Oncology • Transplantation • HLA-DRB1

[VIRTUAL] THE IMPACT OF GVHD ON OUTCOMES AFTER ADULT SINGLE CORD BLOOD TRANSPLANTATION IN EUROPEAN AND JAPANESE POPULATIONS: THE EUROCORD/ALWP EBMT AND JSHCT/JDCHCT COLLABORATIVE STUDY (EBMT 2021) - " The deleterious impact of severe acute GVHD was observed in both registries. On the other hand, mild GVHD, i.e. grade II acute GVHD and limited chronic GVHD showed a beneficial effect in the Japanese cohort only. This could reflect ethnic differences in UCBT outcomes and might contribute to the preference of UCBT in Japan."

Clinical • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Oncology • Transplantation • HLA-DRB1

[VIRTUAL] Impact of Graft-Versus-Host Disease on Lymphoma Progression after Allogeneic Stem Cell Transplantation: Retrospective Analysis from the Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) (TCT-ASTCT-CIBMTR 2021) - "Considering the high risk of lymphoma progression after allo-HSCT, it is not the best measure to minimize the risk of GVHD in all NHL patients. Inducing the optimal GVHD/GVL effect according to each patient’s condition and optimizing the managements of GVHD might be the keys to ameliorate transplant outcomes, since the benefits of GVL effect were often offset by high TRM."

Retrospective data • Graft versus Host Disease • Hematological Malignancies • Immunology • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

[VIRTUAL] Impact of Graft-Versus-Host Disease on Lymphoma Progression after Allogeneic Stem Cell Transplantation: Retrospective Analysis from the Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) (TCT-ASTCT-CIBMTR 2021) - "Considering the high risk of lymphoma progression after allo-HSCT, it is not the best measure to minimize the risk of GVHD in all NHL patients. Inducing the optimal GVHD/GVL effect according to each patient’s condition and optimizing the managements of GVHD might be the keys to ameliorate transplant outcomes, since the benefits of GVL effect were often offset by high TRM."

Retrospective data • Graft versus Host Disease • Hematological Malignancies • Immunology • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

[VIRTUAL] Impact of Graft-Versus-Host Disease on Lymphoma Progression after Allogeneic Stem Cell Transplantation: Retrospective Analysis from the Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) (TCT-ASTCT-CIBMTR 2021) - "Considering the high risk of lymphoma progression after allo-HSCT, it is not the best measure to minimize the risk of GVHD in all NHL patients. Inducing the optimal GVHD/GVL effect according to each patient’s condition and optimizing the managements of GVHD might be the keys to ameliorate transplant outcomes, since the benefits of GVL effect were often offset by high TRM."

Retrospective data • Graft versus Host Disease • Hematological Malignancies • Immunology • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

[VIRTUAL] Impact of Graft-Versus-Host Disease on Lymphoma Progression after Allogeneic Stem Cell Transplantation: Retrospective Analysis from the Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) (TCT-ASTCT-CIBMTR 2021) - "Considering the high risk of lymphoma progression after allo-HSCT, it is not the best measure to minimize the risk of GVHD in all NHL patients. Inducing the optimal GVHD/GVL effect according to each patient’s condition and optimizing the managements of GVHD might be the keys to ameliorate transplant outcomes, since the benefits of GVL effect were often offset by high TRM."

Retrospective data • Graft versus Host Disease • Hematological Malignancies • Immunology • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

[VIRTUAL] Impact of Graft-Versus-Host Disease on Lymphoma Progression after Allogeneic Stem Cell Transplantation: Retrospective Analysis from the Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) (TCT-ASTCT-CIBMTR 2021) - "Considering the high risk of lymphoma progression after allo-HSCT, it is not the best measure to minimize the risk of GVHD in all NHL patients. Inducing the optimal GVHD/GVL effect according to each patient’s condition and optimizing the managements of GVHD might be the keys to ameliorate transplant outcomes, since the benefits of GVL effect were often offset by high TRM."

Retrospective data • Graft versus Host Disease • Hematological Malignancies • Immunology • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

[VIRTUAL] ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR FOLLICULAR LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANTATION (EBMT 2020) - "The cumulative incidences of acute (> grade II) and chronic graft-versus-host disease (GVHD) were 34.9% (95%CI, 27.1-42.8%) at day 100 and 29.5% (95%CI, 22.1-37.4%) at 1 year, respectively... Despite high NRM, the results of our study suggest that allo-SCT is a curative treatment in patients with FL relapsing even after an auto-SCT."

Anaplastic Thyroid Cancer • Follicular Lymphoma • Gastric Cancer • Gastrointestinal Cancer • Graft versus Host Disease • Head and Neck Cancer • Hematological Malignancies • Immunology • Lymphoma • Myelodysplastic Syndrome • Oncology • Oral Cancer • Solid Tumor • Thyroid Cancer • Transplantation

[VIRTUAL] ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR FOLLICULAR LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANTATION (EBMT 2020) - "The cumulative incidences of acute (> grade II) and chronic graft-versus-host disease (GVHD) were 34.9% (95%CI, 27.1-42.8%) at day 100 and 29.5% (95%CI, 22.1-37.4%) at 1 year, respectively... Despite high NRM, the results of our study suggest that allo-SCT is a curative treatment in patients with FL relapsing even after an auto-SCT."

Anaplastic Thyroid Cancer • Follicular Lymphoma • Gastric Cancer • Gastrointestinal Cancer • Graft versus Host Disease • Head and Neck Cancer • Hematological Malignancies • Immunology • Lymphoma • Myelodysplastic Syndrome • Oncology • Oral Cancer • Solid Tumor • Thyroid Cancer • Transplantation

[VIRTUAL] ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR FOLLICULAR LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANTATION (EBMT 2020) - "The cumulative incidences of acute (> grade II) and chronic graft-versus-host disease (GVHD) were 34.9% (95%CI, 27.1-42.8%) at day 100 and 29.5% (95%CI, 22.1-37.4%) at 1 year, respectively... Despite high NRM, the results of our study suggest that allo-SCT is a curative treatment in patients with FL relapsing even after an auto-SCT."

Anaplastic Thyroid Cancer • Follicular Lymphoma • Gastric Cancer • Gastrointestinal Cancer • Graft versus Host Disease • Head and Neck Cancer • Hematological Malignancies • Immunology • Lymphoma • Myelodysplastic Syndrome • Oncology • Oral Cancer • Solid Tumor • Thyroid Cancer • Transplantation

[VIRTUAL] ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR FOLLICULAR LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANTATION (EBMT 2020) - "The cumulative incidences of acute (> grade II) and chronic graft-versus-host disease (GVHD) were 34.9% (95%CI, 27.1-42.8%) at day 100 and 29.5% (95%CI, 22.1-37.4%) at 1 year, respectively... Despite high NRM, the results of our study suggest that allo-SCT is a curative treatment in patients with FL relapsing even after an auto-SCT."

Anaplastic Thyroid Cancer • Follicular Lymphoma • Gastric Cancer • Gastrointestinal Cancer • Graft versus Host Disease • Head and Neck Cancer • Hematological Malignancies • Lymphoma • Myelodysplastic Syndrome • Oncology • Oral Cancer • Thyroid Cancer • Transplantation

A novel and innovative paper-based analytical device for assessing tear lactoferrin of dry eye patients. (PubMed, Ocul Surf) - "The novel μPAD may pave the way for measuring lactoferrin concentration in tear fluid from DED patients. Our results suggested that lactoferrin concentration in tear fluid reflect the severity of DED."

Clinical • Journal • Dry Eye Disease • Graft versus Host Disease • Ophthalmology

Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Myelodysplastic Syndrome in Adolescent and Young Adult Patients (ASH 2018) - "Covariates were as follows: age (16-29 vs 30-39), sex (male vs female), Performance Status (PS) according to the Eastern Cooperative Oncology Group (0-1 vs 2-4), disease status (active vs non-active), karyotype risk according to the International Prognostic Scoring System (IPSS, good vs intermediate vs poor), conditioning regimen (Reduced intensity conditioning regimen [RIC] vs myeloablative conditioning regimen), donor type (related bone marrow transplantation [BMT] or peripheral blood stem cell transplantation [PBSCT] vs unrelated BMT or PBSCT vs cord blood transplantation [CBT]), prophylaxis of graft-versus-host disease (tacrolimus-based vs cyclosporine A-based), and years of HSCT (2000-2007 vs 2008-2015). Conclusion In the present study, the epidemiology of AYA patients with MDS who received allogeneic HSCT for the first time, and the prognostic factors influencing 5yOS were evaluated. Our results provide physicians with additional information for the treatment of..."

Clinical • Biosimilar • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Infertility • Long-acting Reversible Contraceptives • Myelodysplastic Syndrome • Oncology • Transplantation

REFRACTORY GRAFT-VERSUS-HOST DISEASE-FREE, RELAPSE-FREE SURVIVAL: PROPOSAL OF A SIMPLE AND ACCURATE ENDPOINT TO EVALUATE THE LONG-TERM SUCCESS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (EBMT 2018) - "We showed that cGRFS and rGRFS more accurately reflect long-term transplant success than conventional GRFS. Especially, rGRFS can be easily calculated and analyzed with widely-used statistical approaches including proportional hazard modeling. Therefore, we propose rGRFS as a more effective and simple endpoint for assessing the long-term transplant success."

Biosimilar • Graft versus Host Disease • Immunology

IL-6 producing donor-derived macrophages contribute to the development of ocular chronic graft-versus-host disease in mice. (ARVO 2020) - "The percentage of GFP+CD68+IL-6+ cells were significantly higher in the GVHD group (N=4) compared to the control group (N=5) 8 weeks after BMT. The serum level of IL-6 was gradually increased after the onset of GVHD.Conclusions Our results suggest that there could be an association between the donor-derived macrophages producing IL-6 and the development of lacrimal gland cGVHD."

Preclinical • IL6

The correlation in the microbiome analysis of the conjunctiva and the gut between ocular graft-versus-host disease patients and graft-versus-host disease model mice. (ARVO 2020) - "Interestingly, a similar trend was observed in untreated mice with GVHD and antibiotics-administrated ones in which ocular and systemic GVHD was profoundly reduced.Conclusions We found a similar tendency in the 16S rRNA microbiome analysis between GVHD patients and a mouse model of GVHD. The results suggest that a similar microbiome is involved in the development of ocular GVHD in humans and mice."

Analysis of factors related to refractive changes around onset of dry eye disease caused by chronic graft-versus-host-disease after hematopoietic stem cell transplantation (ARVO 2020) - "We found that there is difference between the area of corneal epithelial disorder, and inferior disorder especially occurred in the cases with refractive changes, compared to the central and superior disorder (p<0.05).Conclusions The frequency of myopic changes in the cGVHD-related DED patients were significantly higher than that of the controls. Since corneal epithelial disorder of central location was significantly low than that of inferior location, corneal disorder might not influence the refractive change among some factors related to myopia in the cGVHD patients."

PHASE II TRIAL OF FECAL MICROBIOTA TRANSPLANTATION FOR STEROID-RESISTANT GASTROINTESTINAL ACUTE GVHD (EBMT 2020) - "FMT can be an effective treatment option for GI-aGVHD. Restoring GI microbial diversity in the early phase of FMT might be a key factor for the success of FMT. Our results also indicate that there might be a discrepancy between local and systemic immune response in FMT."

P2 data • CD8

CLINICAL CHARACTERISTICS OF HUMAN HERPES VIRUS-6 (HHV-6) MYELITIS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (EBMT 2019) - "...Cyclosporine or tacrolimus in combination with short-term methotrexate was used for graft-versus-host disease (GVHD) prophylaxis...All patients were promptly treated with antiviral agents such as ganciclovir and foscarnet... Not only encephalitis but also myelitis should be recognized as the CNS disorders due to HHV-6 after allo-HSCT. Pruritis and/or pain could be the initial symptoms. With an early intervention with the effective antiviral agent, HHV-6 myelitis could be successfully managed."

Clinical